Companies
Founded
Exits
Patent
Applications (Filed)
We are a multi-disciplinary life sciences lab focused on developing and commercializing
breakthrough innovations. We seek to understand the biggest challenges in healthcare
and develop innovative and effective treatment solutions that have the potential to
improve the lives of millions of patients.
Oral Biologics Delivery vs. Making Oral Biologics a Reality
The concept for Rani was developed by Mir Imran, a prolific medical inventor and entrepreneur who has founded more than twenty life sciences companies.
Rani was established as a company in 2012 after several years as a research project within InCube Labs, Mir’s multi-disciplinary life sciences lab focused on developing and commercializing breakthrough innovations.
The Rani platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases.
View Company
Treatment of overactive bladder with sacral nerve stimulation
SacraMed is a medical technology company focused on the development of a neuromodulation system for the treatment of Overactive bladder (OAB). OAB is a bladder disorder that results in an abnormal urge to urinate, with or without urinary incontinence.
It can occur at any age, but is most common in the elderly population. Approximately 1 in 6 adults suffers from OAB. It is a treatable condition, and at SacraMed we are working on advancing the tools and techniques to help bring relief to patients.
Breakthrough Therapy for Iron Deficiency Anemia
Fe3 is an early stage company developing a novel transdermal therapy for the treatment of iron deficiency anemia. The approach and technology for Fe3 was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.
25 million people in the US alone have mild to moderate anemia, making it one of the most prevalent micro-nutrient deficiencies.
Medical Therapy to
Treat Epilepsy
Neurolink is an early stage company developing a novel therapy for the treatment of epilepsy.
Nearly three million Americans suffer from epilepsy, a neurological condition characterized by seizures. One of the most common neurological diseases, epilepsy affects approximately 1% of the population - 1 in 26 people will have epilepsy in their lifetime.
Implantable drug-device combination therapy for brain cancer
Theracle is developing an implantable drug-device combination therapy for gliomas.
The approach uses an implantable drug-delivery device, bypassing the blood-brain barrier. The device will provide an ability to focus treatment directly at the cancer site using one or more drugs, and it is expected that treatment will result in no peripheral adverse effects. It is planned to pursue an FDA orphan drug designation, with fast-track status towards regulatory approval.
View CompanyInCube has a broad and deep network of resources in a variety of disciplines including clinical, regulatory, reimbursement, manufacturing, and quality as well as investors and corporate, academic and government partners. We also have close collaborations with InCube Ventures, VentureHealth and Modulus which provide funding and manufacturing support to our portfolio companies.
View NetworkOur innovation process is centered on the identification and framing of a clinical problem that is worthy of a new solution. Throughout the years, we have addressed a number of clinical needs with implantable devices, drug delivery combinations, interventional devices and the use of novel biomaterials. Throughout our innovation process, we develop robust intellectual property.
Our objective is to create new therapies that will have a significant and positive impact on patients. This starts with identifying the most important problems in healthcare, those with few or inadequate current solutions.
Overactive bladder affects millions of patients and is a growing problem with our aging population. In addition, neurogenic bladder can lead to a number of urinary conditions in people who lack bladder control due to brain, spinal cord or nerve problems. These conditions are debilitating and can dramatically affect a person’s quality of life. Our team is developing novel solutions for the treatment of urological conditions including implantable neuromodulation devices.
Mir Imran is recognized as one of the leading inventors and entrepreneurs in the healthcare field. Mir has created two dozen companies, many of which have successfully exited through acquisition or IPO. He now holds more than 600 issued or pending US patents and many of his innovations have become standards of care.
MORE ON MIR